Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:53:40.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including a shift from a Phase 2 multicenter study to a single arm trial format for the treatment of malignant melanoma, with a new focus on the collaboration with Merck Sharp & Dohme LLC. Additionally, the principal investigator has been updated to Pier Fr Ferrucci, MD.
    Difference
    58%
    Check dated 2025-04-16T01:44:39.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T20:23:40.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T18:26:25.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:21:07.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T05:06:06.000Z thumbnail image

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.